Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Fortress Biotech, Inc.NASDAQ: FBIO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $16.04M rose 22.1% year over year, ahead of the +14.5% change in trailing-twelve-month revenue. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $76.75M (+21.3%) for the fiscal year ending Dec 2026, a step up from the +9.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.04M-0.3% QoQ
Last fiscal yearDec 2025
$63.26M+9.7% YoY
LTMMar 2026
$66.16M+14.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.1%+11.5%-10.6 pp
1 year+9.7%+21.3%+11.6 pp
3-year CAGR-5.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
63.26M USD
Year-over-year change
+9.7%
4-year CAGR
-2.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 revenue of $66.16M is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +14.5% is the 3rd highest of 4, against a peer median of +106.7%.
  • Over three fiscal years its annual growth of -5.8% compares with a peer median of -3.4%.
FBIO Competitors Peer median
Revenue for FBIO and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026$255.61M +439.3%+1204.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$66.16M +14.5%-5.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$9.14M +106.7%-8.6%
NTRBNutriband Inc.LTM Apr 2026$1.8M -24.8%-0.7%
ADAGAdagene Inc.LTM Jun 2024$815.75K —-6.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ——
IMUXImmunic, Inc.LTM Mar 2026$0 ——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ——
XBITXBiotech Inc.LTM Mar 2026$0 ——
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ——
Peer median (excluding FBIO) $0+106.7%-3.4%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.79M75.74M84.51M57.68M63.26M
Cost of Revenue32.08M30.78M22.89M20.88M20.92M
Gross Profit36.71M44.97M61.62M36.8M42.34M
Gross Margin53.4%59.4%72.9%63.8%66.9%
Research & Development128.87M134.88M106.07M56.88M11.9M
Selling, General & Admin86.84M113.66M90.98M87.73M96.4M
Operating Expenses225.25M248.53M203.96M147.18M112.56M
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
EBITDA(146.17M)(193.69M)(135.72M)(104.49M)(20.17M)
EBITDA Margin-212.5%-255.7%-160.6%-181.2%-31.9%
Operating Income(188.54M)(203.56M)(142.34M)(110.38M)(70.22M)
Operating Margin-274.1%-268.8%-168.4%-191.4%-111.0%
Interest Income649K1.4M3M2.68M2.49M
Interest Expense15.31M13.64M12.52M9.93M8.71M
Other Income / Expenses24.19M(9.9M)(11.29M)(10.16M)36.69M
Income Before Tax(164.35M)(213.46M)(153.63M)(120.54M)(33.54M)
Pre-Tax Margin-238.9%-281.8%-181.8%-209.0%-53.0%
Income Tax Expense473K449K521K312K(620K)
Net Income(64.7M)(86.58M)(60.64M)(46M)6.82M
Net Margin-94.1%-114.3%-71.7%-79.8%10.8%
EPS (Basic)(11.85)(14.55)(8.47)(2.69)(0.07)
EPS (Diluted)(11.85)(14.55)(8.47)(2.69)(0.07)
Weighted Avg Shares5.45M5.93M8.11M20.78M27.9M
Weighted Avg Shares (Diluted)5.45M5.93M8.11M20.78M279.02M

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.